What is HC Wainwright’s Estimate for INO FY2024 Earnings?

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) – Stock analysts at HC Wainwright upped their FY2024 EPS estimates for Inovio Pharmaceuticals in a research note issued on Monday, November 18th. HC Wainwright analyst R. Selvaraju now forecasts that the biopharmaceutical company will post earnings of ($4.39) per share for the year, up from their prior estimate of ($4.64). HC Wainwright currently has a “Neutral” rating and a $5.00 price objective on the stock. The consensus estimate for Inovio Pharmaceuticals’ current full-year earnings is ($4.68) per share. HC Wainwright also issued estimates for Inovio Pharmaceuticals’ Q4 2024 earnings at ($1.03) EPS, Q1 2025 earnings at ($1.08) EPS, Q2 2025 earnings at ($0.90) EPS, Q3 2025 earnings at ($0.78) EPS, Q4 2025 earnings at ($0.68) EPS and FY2025 earnings at ($3.35) EPS.

INO has been the subject of several other reports. Royal Bank of Canada dropped their target price on Inovio Pharmaceuticals from $7.00 to $6.00 and set a “sector perform” rating for the company in a research report on Friday, November 15th. Oppenheimer dropped their price objective on shares of Inovio Pharmaceuticals from $33.00 to $15.00 and set an “outperform” rating for the company in a report on Monday. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company. According to data from MarketBeat, Inovio Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $38.00.

Inovio Pharmaceuticals Price Performance

NASDAQ INO opened at $3.97 on Wednesday. Inovio Pharmaceuticals has a twelve month low of $3.85 and a twelve month high of $14.75. The business’s fifty day moving average is $5.61 and its 200 day moving average is $8.00.

Hedge Funds Weigh In On Inovio Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of INO. Bank of New York Mellon Corp acquired a new position in Inovio Pharmaceuticals in the second quarter valued at approximately $661,000. Signature Estate & Investment Advisors LLC acquired a new position in shares of Inovio Pharmaceuticals during the 2nd quarter valued at $88,000. Rhumbline Advisers boosted its stake in Inovio Pharmaceuticals by 5,943.0% during the second quarter. Rhumbline Advisers now owns 38,494 shares of the biopharmaceutical company’s stock worth $311,000 after acquiring an additional 37,857 shares in the last quarter. American Century Companies Inc. grew its holdings in Inovio Pharmaceuticals by 62.2% in the second quarter. American Century Companies Inc. now owns 31,565 shares of the biopharmaceutical company’s stock worth $255,000 after purchasing an additional 12,100 shares during the period. Finally, Cornercap Investment Counsel Inc. bought a new stake in Inovio Pharmaceuticals in the second quarter valued at $184,000. Institutional investors and hedge funds own 26.79% of the company’s stock.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.